The Role of CD38 in Predicting Outcomes for Non-M3 Acute Myeloid Leukemia Patients

doi:10.21203/rs.3.rs-5266029/v1

Download PDF

Research Article

The Role of CD38 in Predicting Outcomes for Non-M3 Acute Myeloid Leukemia Patients

https://doi.org/10.21203/rs.3.rs-5266029/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Introduction:

Acute myeloid leukemia (AML) is a rare but aggressive type of cancer with different survival rates around the world. While factors such as age, cytogenetic, and molecular abnormalities play an important role that impacts the prognosis of AML patients, we investigated the correlation between CD38 and other hematologic markers and the survival of AML patients for therapy initiation.

Methods

In this retrospective cohort study, we relied on flow cytometry to examine CD38 expression on AML blasts and evaluated its correlation with overall survival (OS) and one-year survival in newly diagnosed AML patients at the Hematology-Oncology Research Center, Iran, Tabriz.

Results

Seventy-two newly diagnosed non M3-AML patients were followed in this study. The results showed there was a significant relationship between overall survival and one year survival CD38 levels. Besides, Increasing of CD38 level by 1% increased the hazard of mortality by 1 percent (HR = 0.99; 95% CI: 0.98 to 1.01).

Conclusion

The expression of certain membrane molecules like CD38 on leukemic cells can provide valuable information about the prognosis of AML patients and their treatment options.

Acute myeloid leukemia

CD38

Prognosis

Survival

AML

Adults suffering acute leukemia tend to acquire acute myeloid leukemia (AML). It is a type of hematologic malignancy which has heterogenic clinical and molecular features. AML can develop quickly, with fast progression that can be fatal. Even with prolonged chemotherapy and tailored medicines, adult AML patients have extremely low survival rates. For those suffering AML aged over 65, the chance of surviving for five years is less than 5%.(1) Unlike the poor prognosis of this disease, its treatment has not changed much in recent decades, and high-dose chemotherapy is still the basis of treatment.(2) In many patients receiving standard chemotherapy, complete remission (CR) is seen, while many of them relapse due to therapy resistant leukemic cells. Clinical findings such as advanced age, history of exposure to radiotherapy or cytotoxic agents, history of previous myelodysplasia or other blood disorders such as myeloproliferative neoplasms, and cytogenetic or molecular findings in tumor cells is helpful in patients with AML to predict the possibility of CR and disease-free survival (DFS).(3) Studies have shown that increasing the expression of some membrane molecules such as CD25, CD40, and CD11a are effective in poor prognosis of AML detection.(4, 5) Accurate risk assessment is crucial in tailoring consolidation treatment strategies for AML, whether through chemotherapy, autologous, or allogeneic stem cell transplantation. As a result, the discovery of new predictive markers is essential to improve relapse prediction and new treatment strategies.(6)

One promising target in AML therapy is CD38, a type II transmembrane glycoprotein that plays a role in essential cellular functions, such as calcium signaling, cell adhesion, and intracellular signal transduction.(7) While CD38 is expressed in various cell types, its overexpression in hematological cancers, including AML, has made it an attractive target for monoclonal antibody therapies. The identification of CD38 as a potential therapeutic target in AML has led to increased interest in understanding its contribution to leukemia cell survival and the therapeutic benefits of targeting this molecule.(8)

Recent research has shown that CD38 inhibition in AML not only affects the survival of leukemic cells but also interrupts the critical interactions between these cells and their surrounding microenvironment within the bone marrow demonstrated that blocking CD38 hinders the movement of leukemic cells and enhances their clearance through phagocytosis, both of which are crucial to slowing disease progression.(9) Moreover, CD38 is involved in the transfer of mitochondria from mesenchymal stromal cells (MSCs) to leukemic cells, a process vital for the metabolic support of leukemia cells. Inhibition of CD38 with daratumumab has been shown to prevent this mitochondrial transfer, thereby reducing the metabolic function of AML cells and limiting their ability to survive.(10) Furthermore, combining CD38-targeted therapies with other treatments has shown potential to boost therapeutic effectiveness. One notable example is the combination of daratumumab with venetoclax, a BCL-2 inhibitor that induces apoptosis by blocking BCL-2. While venetoclax alone has demonstrated success in AML treatment, the addition of daratumumab has produced enhanced therapeutic outcomes in preclinical models. This combination has shown synergistic effects, suggesting it may provide better results for patients with AML.(11) These observations provide strong motivation for investigating CD38-targeted treatments in conjunction with existing therapies for AML.

The therapeutic impact of CD38 inhibition extends beyond the direct targeting of leukemic cells. Research has highlighted that CD38 plays a crucial role in the interactions within the bone marrow microenvironment, which supports leukemia cell survival. This includes disrupting the signaling between leukemia cells and the bone marrow niche, which supplies critical survival signals to the leukemic cells. As AML progression and relapse are often influenced by these supportive interactions, targeting CD38 could potentially disrupt these mechanisms, offering hope for improved long-term outcomes.(12)

Given the growing preclinical evidence supporting CD38 as a viable therapeutic target, this study aims to investigate the relationship between CD38 expression levels and overall survival in AML patients. A better understanding of how CD38 expression correlates with patient outcomes could help optimize treatment strategies and ultimately improve survival rates in this challenging malignancy.

All the newly diagnosed nonM3 AML patients referred to Shahid Ghazi Tabatabai Hospital, Tabriz, Iran, in 4 years (2017–2021) were included in this study. We determined the sample size with the reasoning that all newly diagnosed patients with non-ALM3 were included, in accordance with the study conducted by Raisi et al.(13)The study protocol was approved by the ethics committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1400.442). Patients’ disease had been confirmed by flow-cytometry of bone marrow samples. Patients diagnosed with acute lymphoblastic leukemia (ALL) and acute promyelocytic leukemia (APL) were not considered in this study.

A standardized treatment plan was applied to all patients. This started with induction therapy using a 3 + 7 regimen (daunorubicin at 45 mg/m² and cytosine arabinoside at 100 mg/m²), followed by two cycles of a 5 + 2 regimen after remission (daunorubicin at 45 mg/m² for 2 days, and cytosine arabinoside at 100 mg/m² for an additional 5 days). For patients who did not achieve CR morphologically after the first round of induction chemotherapy, treatment was escalated with cytosine arabinoside at 500 mg/m² administered via slow intravenous push twice daily for 7 days, along with Novantrone at 12 mg/m² daily for 3 days.

Bone marrow samples stored in anticoagulant ethylenediaminetetraacetic acid (EDTA) tubes were prepared as a suspension. Operating with a cytochemistry technique with a H1 autoanalyzer (Technicon, USA) cell counts were performed. Leukocyte numbers adjusted to between 5,000 and 10,000 cells per microliter. After that samples were stained directly with antibodies (monoclonal) conjugated with fluorescent markers. Flowcytometry was performed using BD FACS callibur device and cell guest software and dedicated panel was used directly against specific antigens, especially CD38, CD64, CD33, CD117, and HLA DR. A 20% threshold was set to determine cases positive for CDs.

After achieving CR, the patients were monitored monthly during the first year and then annually. The primary outcomes of interest were overall survival (OS) and one-year survival. OS was outlined as the duration from the AML diagnosis to either leukemia caused death or the last follow-up date (December 2021).

The normality of the baseline patient characteristics was evaluated utilizing a skewness test, and the based on the outcomes, the data were presented as counts and percentages or as mean (± SD). To categorize quantitative values, median values were computed and used as thresholds to distinguish between high and low expression levels. The following points were applied for other parameters: hemoglobin, < 8 and ≥ 8 g/dL; WBC, < 4,000 and ≥ 4,000 /mm3; Neutrophil < 100 and ≥ 100 /mm3; and platelets, < 50,000 and ≥ 50,000 /mm3.

For the survival analyses, we utilized the Kaplan–Meier method along with log-rank tests to evaluate the prognostic effects of CD38, CD64, CD117, CD33, and HLA DR expressions on AML patients, independently. Additionally, Cox proportional hazards regression analysis was carried out to determine the 95% confidence intervals (CIs), standard errors, and hazard ratios (HRs) for the prognostic factors.

The worth of the prognostic indexes on OS and one-year survival was assessed using the Kaplan–Meier method and log-rank tests. Using STATA 11.0. a p-value of ≤ 0.05 was deemed statistically significant.

In this retrospective cohort 72 newly diagnosed non M3-AML patients were followed in this study. Of them 45.8% (n = 33) were male and 54.2% (n = 39) were female. The Kolmogorov-Smirnov test indicated that the age distribution did not follow a normal distribution (p < 0.001). The age of 33.3% (n = 24) were older than 60 years with the mean of 50.29 ± 18.38 years. AML subtypes were diagnosed as M1 (n = 16, 22.2%), M2 (n = 21, 29.2%), M4 (n = 21, 29.2%) and M5 (n = 14, 19.4%). Overall survival (OS) was 37.5% with the mean of 336.41 days (95% CI; 249.87 -422.95) and median 219 days (95% CI; 249.87 -422.95). Demographic characterestics of included patients summarized in Table 1.

Table 1

Demographic characterestics of included patients
Variable	Category	Number (%)
Variable	Category	Mean ± SD (Median)
Age		36 ± 20.19 (36)
Gender	Male	308 (62.2)
Gender	Female	186 (37.6)
AML subtypes	0	2 (2.8)
	1	7 (9.7)
	2	14 (19.4)
	4	14 (19.4)
	5	5 (6.9)
	None M3	30 (41.7)
CD markers	CD38	84.208 ± 16.3526
	CD64	28.39 ± 28.504
	CD33	67.89 ± 86.452
	CD117	47.9 ± 31.926
	HLA DR	39.35 ± 29.922
Hematologic factors	WBC	3554.07 ± 4452.38
	Hb	6.197 ± 3
	Plt	5587.86 ± 4731.60
	Neut	22.3873 ± 25.55
Outcome	Death	45 (62.5)
Outcome	Survival duration	224.18 ± 222.648

Furthermore, CD38 expression mean was 84.21% (± 16.35) which is more than 20% cutoff. Therefore, Log rank test of equality of survival distributions for the different levels of CD38 showed that there was a significant relationship between overall survival and CD38 levels (P log rank < 0.000).

One year survival rate was 18% (95% CI; 0.08 to 0.31) and there was significant relationship between CD38 levels and one year survival rates (P log rank < 0.000). However Stratified log-rank test for equality of survivor functions adjusted for CD38 level, revealed that one-year survival rates were significantly associated with age (P log rank < 0.000), and gender (P log rank < 0.000) of AML patients, means that female and ≥ 60 years old patients had significantly lower one-year survival rates. Cox-regression analysis at univariate level showed that increasing of CD38 level by 1% increased the hazard of mortality by 1 percent (HR = 0.99; 95% CI: 0.98 to 1.01).

Hazard of mortality was 1.17 times higher in ≥ 60 years vs < 60 years AML patients (HR = 1.17; 95% CI: 0.63–2.16, P = 0.62), but this difference was not statistically significant. This conclusion also applied to some extent to investigate the effect of sex on mortality (HR = 1.17; 95% CI: 0.64–2.12, P = 0.61). Patient characteristics were summarized in Table 1.

In addition to CD38, the effect of other markers including CD64, CD33, CD117, and HLA DR on mortality was investigated by using the 20% cutoff which demonstrated non-significant relations. Among blood markers patients with WBC count of 4000 to 11000 had 2.11-times higher mortality hazard than patients with WBC count less than 4000. The hemoglobin level under 8 mg/dl had about 2 times higher mortality hazard and this was statically significant.

Cox-regression analysis at multivariate level (after adjustment for all confounder variables) showed that AML (M2) subtypes had significantly lower hazard of mortality than other types (HR = 0.34; 95% CI: 0.12–0.93, P = 0.035). However, AMLs with WBC count of 4000–11000 and > 11000 had respectively 4.5- and 2-times higher mortality hazard than patients with WBC count < 4000 (HR = 4.50; 95% CI: 1.24–16.36, P = 0.023) and (HR = 2.05; 95% CI: 0.32–13.28, P = 0.451) (Table 2).

Table 2

Univariable and Multivariable Analysis
Variables		Frequency	Univariable(Unadjusted)
			HR	95%CI		p value	HR	95%CI		p value
				Lower	Upper			Lower	Upper
Age	< 60	48(66.7)	Ref.
Age	≥ 60	24(33.3)	1.17	0.63	2.16	0.62	0.9	0.4	2.01	0.79
Gender	Male	33 (45.8)	Ref.
Gender	Female	39(54.2)	1.17	0.64	2.12	0.61	1.39	0.7	2.77	0.34
CD38*	≥ 20	72(100)	*CD38 expression mean was 84.21% (± 16.35) which is more than 20% cutoff. Therefore, Log rank test of equality of survival distributions for the different levels of CD38
CD38*	< 20	0
CD64	≥ 20	35(48.6)	Ref.
CD64	< 20	37(51.4)	1.62	0.88	2.99	0.12	1.87	0.17	1.3	0.13
CD33	≥ 20	64(88.9)	Ref.
CD33	< 20	8(11.1)	1.01	0.42	2.4	0.98	0.9	0.4	2.01	0.36
CD117	< 20	18(25)	Ref.
CD117	≥ 20	54(75)	1.3	0.63	2.64	0.47	1	0.37	2.6	0.98
HLA DR	< 20	22(30.6)	Ref.
HLA DR	≥ 20	50(69.4)	1.26	0.66	2.41	0.48	1.05	0.44	2.5	0.91
WBC	< 4000	17(23.6)	Ref.
	4000–11000	16(22.2)	2.11	0.9	4.95	0.86	4.5	1.23	16.36	0.23
	> 11000	39(54.2)	2.11	0.95	4.7	0.66	2.05	0.31	13.28	0.45
Hb	≥ 8	30(41.7)	Ref.
Hb	< 8	42(58.3)	2.08	1.11	3.91	0.022	2.25	1.08	4.7	0.03
Plt	> 50000	31(43.1)	Ref.
Plt	≤ 50000	41(56.9)	1.95	1.04	3.64	0.036	1.73	0.77	3.88	0.17
Neut	< 100	11(15.3)	Ref.
	100–500	8(11.1)	0.97	0.3	3.07	0.96	0.52	0.11	2.38	0.4
	500–1500	12(16.7)	0.83	0.27	2.52	0.75	0.4	0.1	1.55	0.18
	> 1500	41(56.9)	1.6	0.64	3.97	0.3	0.68	0.11	4.23	0.68

AML, the most widespread form of acute leukemia in grown up population, has poor survival rates despite extensive chemotherapy and targeted therapies. (1) 45 kDa single-chain transmembrane glycoprotein called CD38 serves as an external catalyst. In addition, it acts as an binding molecule and, under some circumstances, is linked to both cellular proliferation and the prevention and suppression of programmed cell death.(14) There are some studies which assessed the small subpopulations of malignant cells with different immunophenotypes like CD34 + CD38 − or CD34⁺CD38⁻CD123⁺. Increasing evidence suggests that these subpopulations are more resistant to treatment than the majority of leukemia cells and act a key role in the resurgence of the disease following relapse.(15) Whereas, there is a few studies that shows the prognostic effect of CD38 on survival and relatively little has been discovered about the role of CD38 in adult AML patients. Our study illustrated a significant relationship between overall survival and CD38 levels (P log rank < 0.000). Univariate analysis showed that increasing of CD38 level by 1% increased the hazard of mortality by 1 percent (HR = 0.99; 95% CI: 0.98 to 1.01). A study by A. Keyhani et al. with 304 AML patients showed, those with higher CD38 expression had significantly longer durations of complete remission and survival compared to lower levels (P:0.036 and P:0.048, respectively).(16)

In AML, CD33 is a commonly expressed antigen, found in approximately 85–90% of cases. Normally, CD33 expression is limited to early multi-lineage hematopoietic progenitors, myelomonocytic precursors, and more mature myeloid cells, but it is absent in normal pluripotent hematopoietic stem cells. This makes CD33 clinically significant as a potential target for antibody-based therapies in AML.(17) According to the study by Liu et al., patients with high CD33 expression had worse overall survival (OS), with median survival times of 39.0 months compared to 16.7 months (χ² = 13.06, P < 0.001). According to the Cox survival regression analysis, CD33 functions as a separate prognostic factor (HR = 0.233, p = 0.008). Furthermore, univariate analysis revealed that elevated CD33 levels are associated with a poorer prognosis. Whereas, we found the effect of CD33 on mortality demonstrated non-significant relations, as well. (HR = 1.009, p = 0.984)(18)

The FMS-like tyrosine kinase 3 (FLT3), also known as CD135, is a critical class III receptor tyrosine kinase (RTK) involved in hematopoietic development and cellular proliferation. Its expression is prevalent in B-lineage ALL and AML, highlighting its importance in these malignancies. When FLT3 is activated, it triggers a cascade of downstream signaling pathways through the phosphorylation of secondary mediators. These mediators play vital roles in regulating cell differentiation, proliferation, and survival, making FLT3 a key player in the pathophysiology of hematologic cancers.(19) According to M. Raeisi et al.'s study, a low CD135 was substantially correlated with a poor event free survival (EFS) (HR 0.34, 95% CI 0.13–0.88, P = 0.02). Cox-regression analysis revealed a strong association between a low CD135 and a poor OS (HR 0.36, 95% CI 0.14–0.93, P = 0.03). There were no statistically significant correlations seen between the average WBC, CD117 expression level, or CD135 + 117 co-expression and the EFS or the OS. (13)

As a result, CD38 is being investigated as a potential target for new therapies for AML. Some drugs that target CD38 like daratumumab are already approved for use in other types of cancer, such as multiple myeloma, and are being tested in clinical trials for AML. While one of our study limitation is the failure to classify patients cytogenetically due to lack of access to it, more studies are needed regarding the effect of CD38 role in AML prognosis.

Our findings suggest that patients with acute leukemia exhibiting higher CD38 expression, with the exception of AML-M3, may benefit from more intensive therapeutic strategies compared to those with lower CD38 levels. This highlights the importance of CD38 as a potential biomarker for treatment intensity. Additionally, these results pave the way for exploring novel therapeutic approaches targeting CD38 in the management of acute leukemia, potentially improving patient outcomes. Future experimental studies will attempt to uncover the mechanisms that explain why lower levels of CD38 expression are associated with a more favorable prognosis.

Funding

This study received funding from Tabriz University of Medical Sciences for supporting this research study (ID: 66668).

Acknowledgments

The authors would like to thank the patients and the staff of Shahid Ghazi Tabatabai Hospital, Tabriz, Iran.

Conflict of interest

The authors report no conflicts of interest in this work.

Ethical approval

The study protocol was approved by the ethics committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1400.442).

Informed consent

Informed consent was obtained from all the patients for participation in a observational research study. The participation in this study is entirely voluntary. Included participants are free to withdraw from the study at any time without any penalty or loss of benefits.

Consent for publication

Consent for publication was obtained from all the individuals included in the study.

Thein MS, Ershler Wb Fau - Jemal A, Jemal A Fau - Yates JW, Yates Jw Fau - Baer MR, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. (1097-0142 (Electronic)).
Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. (0008-543X (Print)).
Lichtenegger FS, Krupka C, Köhnke T, Subklewe M. Immunotherapy for Acute Myeloid Leukemia. (1532-8686 (Electronic)).
Brouwer RE, Hoefnagel J Fau - Borger van Der Burg B, Borger van Der Burg B Fau - Jedema I, Jedema I Fau - Zwinderman KH, Zwinderman Kh Fau - Starrenburg IC, Starrenburg Ic Fau - Kluin-Nelemans HC, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. (0007-1048 (Print)).
Nakase K, Kita K Fau - Otsuji A, Otsuji A Fau - Anazawa H, Anazawa H Fau - Hoshino K, Hoshino K Fau - Sekine T, Sekine T Fau - Shirakawa S, et al. Diagnostic and clinical importance of interleukin-2 receptor alpha chain expression on non-T-cell acute leukaemia cells. (0007-1048 (Print)).
Swann JB, Smyth MJ. Immune surveillance of tumors. (0021-9738 (Print)).
Van De Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond. Immunological reviews. 2016;270(1):95-112.
Naik J, Themeli M, de Jong-Korlaar R, Ruiter RW, Poddighe PJ, Yuan H, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104(3):e100.
Farber M, Chen Y, Arnold L, Möllmann M, Boog-Whiteside E, Lin Y-A, et al. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Scientific reports. 2021;11(1):22062.
Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, et al. Daratumumab inhibits acute myeloid leukemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells. Haematologica. 2021;106(2):589.
Mistry JJ, Hellmich C, Lambert A, Moore JA, Jibril A, Collins A, et al. Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia. Biomarker research. 2021;9(1):35.
Szlasa W, Czarny J, Sauer N, Rakoczy K, Szymańska N, Stecko J, et al. Targeting CD38 in neoplasms and non-cancer diseases. Cancers. 2022;14(17):4169.
Raeisi M, Nikhanfar AR, Nejate B, Movassaghpour Akbari AA, Dolatkhah R, Roosta Y, et al. Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia. (2476-762X (Electronic)).
Mehta K, Shahid U Fau - Malavasi F, Malavasi F. Human CD38, a cell-surface protein with multiple functions. (0892-6638 (Print)).
Zahran AM, Aly SS, Rayan A, El-Badawy O, Fattah MA, Ali AM, et al. Survival outcomes of CD34(+)CD38(-)LSCs and their expression of CD123 in adult AML patients. (1949-2553 (Electronic)).
Keyhani A, Huh Yo Fau - Jendiroba D, Jendiroba D Fau - Pagliaro L, Pagliaro L Fau - Cortez J, Cortez J Fau - Pierce S, Pierce S Fau - Pearlman M, et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. (0145-2126 (Print)).
Andrews Rg Fau - Torok-Storb B, Torok-Storb B Fau - Bernstein ID, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. (0006-4971 (Print)).
Liu J, Tong J, Yang HA-O. Targeting CD33 for acute myeloid leukemia therapy. (1471-2407 (Electronic)).
Hubbard SR, Till JH. Protein tyrosine kinase structure and function. (0066-4154 (Print)).

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

The Role of CD38 in Predicting Outcomes for Non-M3 Acute Myeloid Leukemia Patients

Status:

Version 1

Abstract

Introduction:

Methods

Results

Conclusion

Introduction

Material and Methods

Results

Discussion

Conclusion

Declarations

References

Additional Declarations

Status:

Version 1